Get started
CERo Therapeutics Holdings, Inc.CERo Therapeutics Holdings, Inc.CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals

CERO fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

CERO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company